168 related articles for article (PubMed ID: 31894014)
1. A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).
Kamarajah SK; Bundred JR; Alrawashdeh W; Manas D; White SA
HPB (Oxford); 2020 May; 22(5):649-659. PubMed ID: 31894014
[TBL] [Abstract][Full Text] [Related]
2. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
Parmar A; Chaves-Porras J; Saluja R; Perry K; Rahmadian AP; Santos SD; Ko YJ; Berry S; Doherty M; Chan KKW
Crit Rev Oncol Hematol; 2020 Jan; 145():102817. PubMed ID: 31955005
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Petrelli F; Parisi A; Tomasello G; Mini E; Arru M; Russo A; Garrone O; Khakoo S; Ardito R; Ghidini M
BMC Gastroenterol; 2023 Jun; 23(1):212. PubMed ID: 37337148
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
6. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of adjuvant gemcitabine
Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle R; Bachet JB; Harlé A; Iovanna J; Hammel P; Rebours V; Turpin A; Ben Abdelghani M; Wei A; Mitry E; Lopez A; Biagi J; François E; Artru P; Lambert A; Renouf DJ; Monard L; Mauduit M; Dusetti N; Conroy T; Cros J
J Clin Oncol; 2024 Mar; 42(9):1067-1076. PubMed ID: 37963313
[TBL] [Abstract][Full Text] [Related]
10. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review].
Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F
Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684
[TBL] [Abstract][Full Text] [Related]
11. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression.
Weniger M; Miksch RC; Maisonneuve P; Werner J; D'Haese JG
Eur J Surg Oncol; 2020 Aug; 46(8):1516-1523. PubMed ID: 32204936
[TBL] [Abstract][Full Text] [Related]
12. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline.
Biagi JJ; Cosby R; Bahl M; Elfiki T; Goodwin R; Hallet J; Hirmiz K; Mahmud A
Curr Oncol; 2023 Jul; 30(7):6575-6586. PubMed ID: 37504342
[TBL] [Abstract][Full Text] [Related]
14. Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials.
Hu Q; Wang X; Chen Y; Li X; Cao P; Cao D
Medicine (Baltimore); 2019 May; 98(21):e15761. PubMed ID: 31124963
[TBL] [Abstract][Full Text] [Related]
15. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC).
Alabd A; Alabd A; Bolaji O; Sugumar K; Ammori J; Hardacre J; Winter JM
Ann Surg Oncol; 2021 Feb; 28(2):1060-1068. PubMed ID: 32968957
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.
Liao WC; Chien KL; Lin YL; Wu MS; Lin JT; Wang HP; Tu YK
Lancet Oncol; 2013 Oct; 14(11):1095-1103. PubMed ID: 24035532
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.
Chan K; Shah K; Lien K; Coyle D; Lam H; Ko YJ
PLoS One; 2014; 9(10):e108749. PubMed ID: 25286060
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Flaum N; Hubner RA; Valle JW; Amir E; McNamara MG
J Surg Oncol; 2019 Jun; 119(7):932-940. PubMed ID: 30838647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
